Application | Comment | Organism |
---|---|---|
medicine | enzyme is a target for development of improved therapies for infection by trypanosomatid parasites | Leishmania major |
Crystallization (Comment) | Organism |
---|---|
enzyme in ternary complex with NADPH and inhibitor 2,4,6-triaminoquinazoline in protein solution containing 10 mg/ml protein, 20 mM sodium acetate, pH 5.3, 1 mM NADPH, 1 mM 2,4,6-triaminoquinazoline, 20 mM DTT, and 1% DMSO, hanging drop vapour diffusion method, against equal volume of 0.002 ml of reservoir solution containing 11-14% PEG 5000, 100 mM sodium acetate, pH 5.5, and 40-140 mM calcium acetate, 20°C, thin grew clumps of thin fragile rods, cryopreservation in a solution of 0% reservoir solution and 30% glycerol, X-ray diffraction structure determination and analysis at 2.6 A resolution, molecular replacement | Leishmania major |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2,4,6-triaminoquinazoline | i.e. TAQ, mimics the pterin head group of methotrexate, binds to the active site, binding structure and inhibition mechanism | Leishmania major | |
methotrexate | antifolate drug | Leishmania major | |
additional information | structure-based inhibitor development | Leishmania major |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
25700 | - |
4 * 25700, crystal structure | Leishmania major |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Leishmania major | Q01782 | - |
- |
Subunits | Comment | Organism |
---|---|---|
tetramer | 4 * 25700, crystal structure | Leishmania major |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NADPH | dependent on | Leishmania major |